What Your Botox Actually Costs You: A Margin Walk for Aesthetic Services

A med spa owner posted a plain question on r/medspa: how do you actually calculate your margins? The thread scored almost nothing and drew thirteen comments, most of them variations on "product cost times markup." Nobody gave the owner a real answer, and I think I know why. The honest answer takes more than one line, and it lands somewhere most owners would rather not look.

Here is the uncomfortable version. The margin number you quote yourself, the one that makes injectables feel like the easiest money in the building, is almost always revenue math wearing a margin costume. When you actually walk the cost of a single Botox visit from vial to redo, the real contribution margin is a fraction of what you assumed, and on a bad visit it is negative. This is the walk.

Start with the product, because the vial is not where the cost ends

Most owners anchor on the vial, so start there and then keep going.

Ward Advisory's med spa analysis puts the acquisition cost of a 100-unit Botox vial at $400 to $600 depending on purchasing volume, which is roughly $4 to $6 a unit, with high-volume buyers landing near the bottom of that range. AbbVie's own published price list puts the Wholesale Acquisition Cost of a 100-unit Botox Cosmetic vial at $656, a figure unchanged from its February 2024 disclosure through its August 2026 catalog, so the discount off list is real but bounded.

The vial also does not yield 100 billable units. Ward Advisory puts reconstitution and overfill waste at 10 to 15 percent, which turns a 100-unit vial into 85 to 90 units you can actually charge for. On a $500 vial that moves your true product cost per billable unit from $5.00 to something closer to $5.55.

On paper, this still looks glorious. Charge $14 a unit against a $5 product cost and injectables read like a 60% to 70% gross business, which is very close to what Ward Advisory reports hearing from owners when it asks them: sixty percent, maybe seventy. That single comparison, product cost against price, is the number almost every owner carries in their head. It is also the number that is wrong, because it stops at the one cost that is easiest to see and ignores the two that actually decide whether the visit made money.

The vial is the floor of your cost, not the ceiling. Everything below is what the "70% margin" story leaves out.

Injector compensation is the line that quietly eats the margin

The next cost is the person holding the syringe, and it is usually booked against the wrong base.

Ward Advisory puts injector commission at commonly 30% to 50% of the service fee, and runs the same arithmetic I would: at a 40% split on $14 a unit you are paying $5.60 per unit to the injector, which is larger than the product itself. Subtract both from the same unit and the $14 that looked like a 60% gross line is carrying $3.40 of contribution, or 24%, before a dollar of rent or a minute of chair time has been counted against it.

Here is the part owners miss. Commission calculated on gross revenue rather than on contribution margin means every price cut and every discounted membership unit is subsidized twice, once by you and once by nobody, because the injector's cut does not shrink when your realized price does. In my work with practices, the ones who discount aggressively to fill the calendar are almost always the ones paying commission on the pre-discount rate, so their busiest injectors are their least profitable ones.

If you only ever add one cost to your mental model, add this one. It is frequently the single largest line in the visit.

Room time and the redo rate are the two costs that never make the sheet

Two more costs decide the real number, and neither shows up on a product invoice.

The first is room and staff time. Independent benchmarking from Vagaro and Optimantra converges on the same band: a mature med spa nets 15% to 25% once rent, front desk, and overhead are absorbed, and Vagaro puts rent alone at 8% to 15% of revenue. That tells you the fully loaded cost of a treatment room is not zero and cannot be waved away. Ward Advisory allocates it straight onto the unit, at $3.00 to $7.50 per Botox unit depending on utilization, which is enough on its own to erase the $3.40 the previous section left standing. A fifteen-minute tox visit and a sixty-minute laser visit do not carry the same overhead, yet most menus price as if they do.

The second is the redo rate. A two-week complimentary touch-up is standard practice in aesthetics, and every touch-up is product and chair time you already sold at full price and are now delivering again at zero additional revenue. Across the practices I have reviewed, nobody tracks their touch-up rate as a cost line, so a 10% redo rate silently converts a thin-but-positive margin into a negative one on those visits, and the owner never sees which injector or which dose protocol is driving it.

Product, labor, room, redo. Four lines, not one. That is the actual cost of the visit.

The Strategic Recommendation

For the next 30 days, before you touch a single price on the menu, build one contribution-margin sheet for your top three services.

Give each service four rows, not one: product cost at your real per-unit acquisition rate including waste, injector compensation at your actual commission structure, allocated room and staff time per minute of chair, and an expected redo cost using your own touch-up rate. Subtract all four from the average realized price, not the list price, because discounts and memberships mean the two differ. The output is a per-service contribution margin, and it is almost certainly lower than the number you have been quoting. Ward Advisory's own conclusion, after running that stack, is that net margin on Botox lands at 5% to 15% for most practices, and at 10% to 35% only for a practice doing 300 or more units a month with disciplined pricing, waste control, and commission structure.

That single sheet changes three decisions at once: which services to promote, how to structure injector commission, and where a "popular" service is actually losing money at volume. You cannot price what you have never fully costed.

Where GrowBien fits

The reason this margin walk almost never gets done is that the four costs live in four systems that do not talk: product invoices in one place, payroll and commission in another, room utilization in your booking software, and redo visits nowhere at all. GrowBien connects those signals so the margin you think is 70% stops hiding the one that is closer to 10%. If you want to see your real per-service contribution margin, book a free marketing review.

Sources: AbbVie, Pharmaceutical Product Wholesaler Acquisition Cost Price List, effective August 7, 2026, listing BOTOX COSMETIC 100 UNIT VIAL (NDC 00023-9232-01) at $656.00, and the same figure in AbbVie's Colorado WAC disclosure for BOTOX Cosmetic, current as of February 2024; Ward Advisory, Botox Profitability: Real Per-Unit Margin and Hidden Costs and Botox Cost Per Unit Med Spa; Vagaro, Med Spa Profit Margins: Averages, Benchmarks and Tips; Optimantra, What Is a Healthy Profit Margin for Med Spas in 2026; the opening thread is "how do you guys calculate your margins?" on r/medspa (score 1, 13 comments), logged in my own June 2026 research pass without a permalink, so treat it as an unlinked first-party note.